Catalog No.
DHB91703
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
Beta-nerve growth factor, NGFB, Beta-NGF, NGF
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01138
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
4D4, AMG-403, JNJ-42160443, CAS: 902141-80-4
Clone ID
Fulranumab
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee, PMID: 25527221
Antibodies to watch in 2016, PMID: 26651519
Anti-nerve growth factor in pain management: current evidence, PMID: 27354823
Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis, PMID: 24452657
Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity, PMID: 24590506
Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues, PMID: 29415946
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial, PMID: 27238963
Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study, PMID: 27101815
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain, PMID: 23748114
Emerging therapies in clinical development and new contributions for neuropathic pain, PMID: 31010688
Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys, PMID: 30852923
Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, PMID: 30368018
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial, PMID: 25008392
Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study, PMID: 28056917
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study, PMID: 27153360
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study, PMID: 27748055
Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies, PMID: 31387410
Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies, PMID: 25527216
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?, PMID: 24691709
Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs, PMID: 33293475
For research use only. Not for human or drug use.
